RESUMEN
AIMS: This study aimed at identifying pharmacological factors such as pharmacogenetics and drug exposure as new predictive biomarkers for delayed graft function (DGF), acute rejection (AR) and/or subclinical rejection (SCR). METHODS: Adult renal transplant recipients (n = 361) on cyclosporine-based immunosuppression were followed for the first 6 months after transplantation. The incidence of DGF and AR were documented as well as the prevalence of SCR at 6 months in surveillance biopsies. Demographic, transplant-related factors, pharmacological and pharmacogenetic factors (ABCB1, CYP3A5, CYP3A4, CYP2C8, NR1I2, PPP3CA and PPP3CB) were analysed in a combined approach in relation to the occurrence of DGF, AR and prevalence of SCR at month 6 using a proportional odds model and time to event model. RESULTS: Fourteen per cent of the patients experienced at least one clinical rejection episode and only DGF showed a significant effect on the time to AR. The incidence of DGF correlated with a deceased donor kidney transplant (27% vs. 0.6% of living donors). Pharmacogenetic factors were not associated with risk for DGF, AR or SCR. A deceased donor kidney and acute rejection history were the most important determinants for SCR, resulting in a 52% risk of SCR at 6 months (vs. 11% average). In a sub-analysis of the patients with AR, those treated with rejection treatment including ATG, significantly less frequent SCR was found in the 6-month biopsy (13% vs. 50%). CONCLUSIONS: Transplant-related factors remain the most important determinants of DGF, AR and SCR. Furthermore, rejection treatment with depleting antibodies effectively prevented SCR in 6-month surveillance biopsies.
Asunto(s)
Funcionamiento Retardado del Injerto/epidemiología , Rechazo de Injerto/epidemiología , Trasplante de Riñón/métodos , Farmacogenética , Adulto , Anticuerpos/inmunología , Biomarcadores/metabolismo , Biopsia , Ciclosporina/uso terapéutico , Funcionamiento Retardado del Injerto/etiología , Funcionamiento Retardado del Injerto/genética , Rechazo de Injerto/etiología , Rechazo de Injerto/genética , Humanos , Inmunosupresores/uso terapéutico , Incidencia , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Prospectivos , Factores de Riesgo , Factores de TiempoRESUMEN
BACKGROUND: The immunosuppressive drug mycophenolate mofetil (MMF), with mycophenolic acid (MPA) as active metabolite, is a nonnephrotoxic alternative to calcineurin inhibitors. Therapeutic drug monitoring (TDM) of MPA may improve clinical benefit from MMF therapy, especially in MMF monotherapy or with reduced dose of a calcineurin inhibitor. Limited data are available on TDM strategies for MPA in orthotopic liver transplantation (OLT). The authors here describe the pharmacokinetic (PK) behavior of MPA after OLT and developed a Bayesian limited sampling model for monitoring MMF after OLT. METHODS: PK data were obtained from 57 stable patients, and trapezoidal area under the curve (AUC(0-12h)) was calculated. The effect of the covariates kidney function and serum albumin concentration was studied. A TDM strategy was developed based on individualized population PKs using Bayesian estimations and limited sampling models to predict the MPA AUC. RESULTS: A relationship between MMF dose and MPA AUC was found and a 8-fold apparent clearance range of MPA was observed at the same dose level. Significant relationships of albumin concentration and creatinine clearance with MPA plasma clearance were identified (respectively, r² = 0.12 and 0.24; P < 0.05). A model with limited sampling at 0, 0.5, 1, 2, and 3 hours after drug administration showed very good correlation with trapezoidal AUC(0-12h) with acceptable bias and precision (r² = 0.92, mean prediction error = 1, mean absolute prediction error = 13; P < 0.05). CONCLUSIONS: Remarkable variability of MPA clearance in stable OLT patients exists, which can be partially explained by the patients' albumin serum levels and creatinine clearance. Systemic exposure in these patients can be accurately assessed by the Bayesian limited sampling TDM strategy.
Asunto(s)
Monitoreo de Drogas/métodos , Inmunosupresores/farmacocinética , Trasplante de Hígado , Ácido Micofenólico/farmacocinética , Adolescente , Adulto , Anciano , Área Bajo la Curva , Teorema de Bayes , Creatinina/metabolismo , Ciclosporina/farmacología , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Femenino , Humanos , Inmunosupresores/sangre , Pruebas de Función Renal , Masculino , Persona de Mediana Edad , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/sangre , Albúmina Sérica/metabolismo , Tacrolimus/farmacología , Adulto JovenRESUMEN
BACKGROUND AND OBJECTIVE: Everolimus is a novel macrolide immunosuppressant used in the prevention of acute and chronic rejection of solid organ transplants. Everolimus is being actively investigated worldwide as a non-nephrotoxic alternative for calcineurin inhibitors. Its highly variable pharmacokinetics and narrow therapeutic window make it difficult to maintain an adequate exposure to prevent serious adverse effects. The primary objective of this study was to improve prediction of everolimus systemic exposure in renal transplant patients by describing the pharmacokinetics of everolimus and identifying the influence of demographic factors and a selection of polymorphisms in genes coding for ABCB1, CYP3A5, CYP2C8 and PXR. The secondary objective of this study was to develop a limited sampling strategy to enable prediction of everolimus exposure in an efficient way and to compare it with the widely used trough blood concentration (C(trough)) monitoring. METHODS: A total of 783 blood samples were obtained from 53 renal transplant patients who had been switched from a triple therapy of ciclosporin, mycophenolate mofetil and prednisolone to a calcineurin inhibitor-free dual therapy of everolimus (twice daily) and prednisolone. Everolimus blood concentrations were analysed in whole blood using liquid chromatography-tandem mass spectrometry during routine therapeutic drug monitoring targeting an area under the blood concentration-time curve from time zero to 12 hours (AUC(12)) of 120 µg · h/L. A population pharmacokinetic model was developed and demographic factors and genetic polymorphisms in genes coding for ABCB1, CYP3A5, CYP2C8 and PXR were included as covariates. In addition, a limited sampling strategy was developed. RESULTS: Maintaining everolimus systemic exposure at an AUC(12) of 120 µg · h/L resulted in low rejection rates but considerable numbers of adverse events and toxicity. Everolimus pharmacokinetics were best described by a two-compartment model with lag-time (oral clearance = 17.9 L/h; volume of distribution of the central compartment after oral administration [V(1)/F] = 148 L and first-order absorption rate constant [k(a)] = 7.36 h-1). Ideal body weight was significantly related to V(1)/F. None of the selected polymorphisms in genes coding for enzymes involved in distribution and metabolism of everolimus had a significant influence on everolimus pharmacokinetics. The pharmacokinetic limited sampling model (C(trough) and whole blood drug concentration at 2 hours postdose [C(2)]) resulted in a significantly improved prediction of everolimus exposure compared with the widely used C(trough) monitoring. CONCLUSION: A two-compartment pharmacokinetic model with lag-time describing the concentration-time profile of oral everolimus in renal transplant patients has been developed using pharmacokinetic modelling. Ideal body weight significantly influenced V(1)/F of everolimus; however, the selected polymorphisms in genes coding for ABCB1, CYP3A5, CYP2C8 and PXR had no clinically relevant effect on everolimus pharmacokinetics. Everolimus C(trough) and C(2) as a limited sampling model can be used to accurately estimate everolimus systemic exposure, an improvement over the widely used C(trough) monitoring.
Asunto(s)
Inmunosupresores/farmacocinética , Trasplante de Riñón , Sirolimus/análogos & derivados , Subfamilia B de Transportador de Casetes de Unión a ATP , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Adulto , Anciano , Hidrocarburo de Aril Hidroxilasas/genética , Citocromo P-450 CYP2C8 , Citocromo P-450 CYP3A/genética , Everolimus , Femenino , Humanos , Inmunosupresores/sangre , Masculino , Persona de Mediana Edad , Modelos Biológicos , Polimorfismo Genético , Receptor X de Pregnano , Receptores de Esteroides/genética , Sirolimus/sangre , Sirolimus/farmacocinética , Adulto JovenRESUMEN
BACKGROUND: There is a need to monitor everolimus blood concentrations in renal transplant recipients as a result of its high pharmacokinetic variability and narrow therapeutic window. However, analytical methods to determine blood concentrations often differ in performance. Therefore, we investigated whether two commonly used therapeutic drug monitoring methods for everolimus were in agreement and to what extent their differences could lead to differences in dosage advice. DESIGN AND METHODS: Six hundred twelve whole blood samples were obtained from 28 adult renal transplant recipients receiving everolimus and prednisolone therapy. These samples included 286 everolimus trough concentrations. The remaining samples were obtained up to 6 hours post everolimus intake and allowed calculation of 84 AUCs0-12h. All samples were analyzed with fluorescence polarization immunoassay (FPIA) on an Abbott TDxFLx analyzer and liquid chromatography-tandem mass spectrometry (LC-MS/MS). RESULTS: Everolimus blood concentrations measured with FPIA and LC-MS/MS were not in agreement. Concentrations determined by FPIA were, on average, 23% higher than concentrations quantified by LC-MS/MS. Moreover, concentrations lower than 15 mug/L or AUC0-12h determined with FPIA could be twofold higher than with LC-MS/MS. This variability can lead to clinically relevant differences in dose adjustment of up to 1.25 mg everolimus despite using a correction factor of 23%. Finally, when trough concentrations were measured with FPIA, higher intrapatient variability was observed compared with the use of LC-MS/MS. CONCLUSION: LC-MS/MS outperforms FPIA for clinical drug monitoring and intervention of everolimus therapy in adult renal transplant recipients on dual therapy with prednisolone. Specifically, the use of FPIA can lead to clinically relevant differences in everolimus dosage advice and higher intrapatient variability.
Asunto(s)
Inmunosupresores/sangre , Trasplante de Riñón/inmunología , Trasplante de Riñón/fisiología , Sirolimus/análogos & derivados , Adulto , Anciano , Área Bajo la Curva , Cromatografía Líquida de Alta Presión , Monitoreo de Drogas/métodos , Everolimus , Femenino , Inmunoensayo de Polarización Fluorescente , Humanos , Inmunosupresores/administración & dosificación , Masculino , Persona de Mediana Edad , Control de Calidad , Reproducibilidad de los Resultados , Sirolimus/administración & dosificación , Sirolimus/sangre , Espectrometría de Masas en TándemRESUMEN
PURPOSE: Optimal ciclosporin A (CsA) exposure in kidney transplant recipients is difficult to attain because of variability in CsA pharmacokinetics. A better understanding of the variability in CsA exposure could be a good means of individualizing therapy. Specifically, genetic variability in genes involved in CsA metabolism could explain exposure differences. Therefore, this study is aimed at identifying a relationship between genetic polymorphisms and the variability in CsA exposure, while accounting for non-genetic sources of variability. METHODS: De novo kidney transplant patients (n = 33) were treated with CsA for 1 year and extensive blood sampling was performed on multiple occasions throughout the year. The effects of the non-genetic covariates hematocrit, serum albumin concentration, cholesterol, demographics (i.e., body weight), CsA dose interval, prednisolone dose and genetic polymorphisms in genes encoding ABCB1, CYP3A4, CYP3A5, and PXR on CsA pharmacokinetics were studied using non-linear mixed effect modeling. RESULTS: The pharmacokinetics of CsA were described by a two-compartment disposition model with delayed absorption. Body weight was identified as the most important covariate and explained 35% of the random inter-individual variability in CsA clearance. Moreover, concurrent prednisolone use at a dosage of 20 mg/day or higher was associated with a 22% higher clearance of CsA, hence lower CsA exposure. In contrast, no considerable genotype effects (i.e., greater than 30-50%) on CsA clearance were found for the selected genes. CONCLUSIONS: It appears that the selected genetic markers explain variability in CsA exposure insufficiently to be of clinical relevance. Therefore, therapeutic drug monitoring is still required to optimize CsA exposure after administration of individualized doses based on body weight and, as this study suggests, co-administration of prednisolone.
Asunto(s)
Peso Corporal , Ciclosporina/administración & dosificación , Ciclosporina/farmacocinética , Inmunosupresores/administración & dosificación , Inmunosupresores/farmacocinética , Trasplante de Riñón , Polimorfismo Genético , Subfamilia B de Transportador de Casetes de Unión a ATP , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Adulto , Anciano , Ciclosporina/sangre , Citocromo P-450 CYP3A/genética , Esquema de Medicación , Femenino , Inmunoensayo de Polarización Fluorescente , Genotipo , Humanos , Inmunosupresores/sangre , Trasplante de Riñón/inmunología , Masculino , Persona de Mediana Edad , Prednisolona/administración & dosificación , Prednisolona/farmacocinética , Receptor X de Pregnano , Receptores de Esteroides/genética , Análisis de SupervivenciaAsunto(s)
Inhibidores de la Calcineurina , Ciclosporina/farmacocinética , Inhibidores Enzimáticos/farmacocinética , Inmunosupresores/farmacocinética , Trasplante de Riñón/inmunología , Tacrolimus/farmacocinética , Ciclosporina/uso terapéutico , Inhibidores Enzimáticos/uso terapéutico , Rechazo de Injerto/tratamiento farmacológico , Humanos , Inmunosupresores/uso terapéutico , Tacrolimus/uso terapéuticoRESUMEN
BACKGROUND: Cytomegalovirus (CMV) infections after transplantation are commonly treated using a prophylactic or preemptive regimen with (val)ganciclovir. It remains unclear, which approach is most effective in preventing CMV disease in D+R- patients. The aim of this retrospective study was to compare the treatment response and antiviral resistance in CMV infections between two treatment regimens in D+R- renal transplant recipients. METHODS: Before 2006, a preemptive treatment regimen with valganciclovir was applied (42 patients). From 2006 onwards, patients first received prophylaxis with valganciclovir for 90 days, followed by a preemptive regimen (29 patients). CMV infections were monitored by regular determination of the CMV DNA load in plasma. Patient charts were reviewed for antiviral treatment data, and resistance was analyzed by nucleotide sequence analysis of the UL97 and UL54 genes in CMV DNA-positive samples. RESULTS: Treatment failure, defined as a CMV DNA load more than or equal to 1000 copies/mL after at least 2 weeks of treatment, occurred less frequently in the prophylaxis cohort than in the preemptive cohort (14% vs. 71%, P<0.001). No CMV end-organ disease occurred in either cohort. Resistant viral isolates were found during treatment in one patient in the prophylaxis cohort versus in three patients in the preemptive group. All CMV infections with resistant virus were cleared without switch of (val)ganciclovir treatment. CONCLUSIONS: Treatment failure of CMV infections occurred less frequently in D+R- renal transplant patients on a sequential prophylaxis-preemptive regimen than in patients on a purely preemptive regimen. Antiviral resistance was observed infrequently and apparently played a minor role in treatment failure.
Asunto(s)
Antivirales/uso terapéutico , Infecciones por Citomegalovirus/tratamiento farmacológico , Infecciones por Citomegalovirus/prevención & control , Citomegalovirus/efectos de los fármacos , Farmacorresistencia Viral , Ganciclovir/uso terapéutico , Trasplante de Riñón/efectos adversos , Insuficiencia del Tratamiento , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales Humanizados , Suero Antilinfocítico/uso terapéutico , Antivirales/administración & dosificación , Basiliximab , Estudios de Cohortes , Citomegalovirus/aislamiento & purificación , Infecciones por Citomegalovirus/epidemiología , Infecciones por Citomegalovirus/virología , Daclizumab , Esquema de Medicación , Femenino , Ganciclovir/administración & dosificación , Ganciclovir/análogos & derivados , Humanos , Inmunoglobulina G/uso terapéutico , Incidencia , Enfermedades Renales/clasificación , Enfermedades Renales/cirugía , Masculino , Persona de Mediana Edad , Proteínas Recombinantes de Fusión/uso terapéutico , Estudios Retrospectivos , ValganciclovirRESUMEN
INTRODUCTION: Chronic allograft nephropathy is the main cause of long-term renal transplant failure. Chronic use of calcineurin inhibitors contributes to its pathogenesis. Here, we report on a multicenter randomized trial to study the effects of withdrawal of cyclosporine A (CsA) from a triple immunosuppressive regimen containing CsA, prednisolone (P), and mycophenolate sodium (MPS) early after transplantation. METHODS: Patients continued on P/CsA, P/MPS, or P and everolimus (EVL). Before withdrawal, a transplant biopsy was performed ensuring no subclinical rejection was present. Drug levels were closely monitored. The primary outcome was interstitial graft fibrosis and hyalinosis. Secondary outcome was among others graft rejection. RESULTS: According to trial regulations, an interim analysis was performed after enrollment of half of the intended number of patients (n=113). Mean follow-up was 14+/-5 months from transplantation and 8+/-5 months from conversion. After conversion, acute rejection percentages were 3% in the P/CsA group, 22% in the P/MPS group, and 0% in the P/EVL group (P<0.009). CONCLUSIONS: We conclude that switching immunosuppressive therapy from P/CsA/MPS to therapy with P/CsA or P/EVL at 6 months after renal transplantation is effective in preventing rejection. Double therapy with P/MPS after withdrawal of P/CsA resulted in an increase in severe acute rejection episodes. These results were the immediate reason to halt the P/MPS arm. Serum creatinine values at the latest follow-up (8+/-5 months after conversion and 14+/-5 months after transplantation) in the P/EVL group were lower than in the P/CsA group.
Asunto(s)
Ciclosporina/administración & dosificación , Rechazo de Injerto/prevención & control , Supervivencia de Injerto/efectos de los fármacos , Inmunosupresores/administración & dosificación , Trasplante de Riñón/efectos adversos , Ácido Micofenólico/administración & dosificación , Prednisolona/administración & dosificación , Sirolimus/análogos & derivados , Adulto , Anciano , Biomarcadores/sangre , Biopsia , Creatinina/sangre , Ciclosporina/efectos adversos , Esquema de Medicación , Monitoreo de Drogas , Quimioterapia Combinada , Everolimus , Femenino , Fibrosis , Rechazo de Injerto/sangre , Rechazo de Injerto/etiología , Rechazo de Injerto/patología , Humanos , Inmunosupresores/efectos adversos , Masculino , Persona de Mediana Edad , Ácido Micofenólico/efectos adversos , Países Bajos , Prednisolona/efectos adversos , Estudios Prospectivos , Sirolimus/administración & dosificación , Sirolimus/efectos adversos , Factores de Tiempo , Resultado del TratamientoRESUMEN
To prevent acute rejection episodes, it is important to reach adequate tacrolimus (TRL) exposure early after kidney transplantation. With a better understanding of the high variability in the pharmacokinetics of TRL, the starting dose can be individualized, resulting in a reduction in dose adjustments to obtain the target exposure. A population pharmacokinetic analysis was performed to estimate the effects of demographic factors, hematocrit, serum albumin concentration, prednisolone dose, TRL dose interval, polymorphisms in genes coding for ABCB1, CYP3A5, CYP3A4, and the pregnane X receptor on TRL pharmacokinetics. Pharmacokinetic data were prospectively obtained in 31 de novo kidney transplant patients randomized to receive TRL once or twice daily, and subsequently, the data were analyzed by means of nonlinear mixed-effects modeling. TRL clearance was 1.5-fold higher for patients with the CYP3A5*1/*3 genotype compared with the CYP3A5*3/*3 genotype (5.5 +/- 0.5 L/h versus 3.7 +/- 0.3 L/h, respectively). This factor explained 30% of the interindividual variability in apparent clearance (exposure). Also, a relationship between the pregnane X receptor A+7635G genotype and TRL clearance was identified with a clearance of 3.9 +/- 0.3 L/h in the A allele carriers versus 5.4 +/- 0.6 L/h in the GG genotype. Finally, a concomitant prednisolone dose of more than 10 mg/d increased the TRL apparent clearance by 15%. In contrast, body weight was not related to TRL clearance in this population. Because patients are typically dosed per kilogram body weight, this might result in underexposure and overexposure in patients, with a low and high body weight, respectively. This integrated analysis shows that adult renal transplant recipients with the CYP3A5*1/*3 genotype require a 1.5 times higher, fixed, starting dose compared with CYP3A5*3/*3 to reach the predefined target exposure early after transplantation.
Asunto(s)
Inmunosupresores/farmacocinética , Trasplante de Riñón , Tacrolimus/farmacocinética , Adulto , Área Bajo la Curva , Peso Corporal , Citocromo P-450 CYP3A/genética , Demografía , Esquema de Medicación , Monitoreo de Drogas , Femenino , Hematócrito , Humanos , Masculino , Tasa de Depuración Metabólica , Persona de Mediana Edad , Polimorfismo Genético , Prednisolona/administración & dosificación , Receptor X de Pregnano , Estudios Prospectivos , Ensayos Clínicos Controlados Aleatorios como Asunto , Receptores de Esteroides/genética , Albúmina Sérica/análisisRESUMEN
OBJECTIVE: To identify predictors of postsurgical adhesion formation in peritoneal fluid and plasma, and assess efficacy and safety of reteplase (recombinant plasminogen activator [r-PA]). DESIGN: Prospective randomized study. SETTING: University Medical Center. PATIENT(S): Twenty-six abdominal myomectomy patients with early second-look laparoscopy (ESL). INTERVENTION(S): Randomization to IP treatment with 1 mg reteplase in 300 mL Ringer's lactate or 300 mL Ringer's lactate only. Scoring of adhesions and collecting peritoneal fluid during both surgical procedures and collecting plasma samples at ten time points. MAIN OUTCOME MEASURE(S): Incidence, severity, and extent of adhesions at ESL. Concentrations of C-reactive protein (CRP), tissue-type plasminogen activator (tPA), plasminogen activator inhibitor 1 (PAI-1), and fibrin degradation products (FbDPs). RESULT(S): Significant correlation between the extent of uterine adhesion formation and preoperative plasma levels of CRP (r(s) = 0.558), PAI-1 (r(s) = 0.413), and the change in tPA concentration in peritoneal fluid from initial surgery to ESL (Delta+PA: r(s) = -0.636). No significant differences in adhesion scores between treatment and control groups. CONCLUSION(S): Our finding that preoperative plasma CRP and PAI-1-levels are significantly correlated with extent of adhesion formation points to a role of chronic inflammation in the disease process. Results are highly indicative for the paradigm that adhesions are caused by an insufficiency in peritoneal fibrinolytic capacity. For successful adhesion prevention therapy relatively high amounts of r-PA are required.
Asunto(s)
Leiomioma/cirugía , Activadores Plasminogénicos/uso terapéutico , Adherencias Tisulares/diagnóstico , Adherencias Tisulares/prevención & control , Neoplasias Uterinas/cirugía , Adulto , Líquido Ascítico/química , Femenino , Procedimientos Quirúrgicos Ginecológicos/efectos adversos , Humanos , Incidencia , Infertilidad Femenina/sangre , Infertilidad Femenina/patología , Infertilidad Femenina/cirugía , Leiomioma/sangre , Leiomioma/diagnóstico , Leiomioma/patología , Miometrio/cirugía , Proyectos Piloto , Complicaciones Posoperatorias/sangre , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/patología , Cuidados Preoperatorios/métodos , Pronóstico , Factores de Riesgo , Adherencias Tisulares/epidemiología , Adherencias Tisulares/etiología , Neoplasias Uterinas/sangre , Neoplasias Uterinas/diagnóstico , Neoplasias Uterinas/patología , Adulto JovenRESUMEN
High busulfan exposure is associated with increased toxicity, for example veno-occlusive disease, whereas low exposure results in less efficacy such as lower engraftment rates. Despite adjusting dose to body weight, interindividual variability in pharmacokinetics and thus drug exposure remained rather large. In this report, the contribution of genetic polymorphisms in the glutathione-S-transferases (GST) isozymes GSTA1, GSTM1, GSTP1, and GSTT1 to the pharmacokinetics of busulfan is studied retrospectively. Seventy-seven children, undergoing myeloablative conditioning for allogeneic hematopoietic stem cell transplantation, were treated with busulfan (Busulvex) during 4 days, receiving busulfan either in one single dose or dived in four doses every 6 hours. Genetic variants of GSTA1, GSTM1, GSTP1, and GSTT1 were determined by pyrosequencing. Pharmacokinetic parameters were estimated by using nonlinear mixed-effect modeling (NONMEM). Subsequently, a combined population pharmacokinetic-pharmacogenetic model was developed describing the pharmacokinetics of busulfan taking into account the GST polymorphisms. In the presented pediatric population, body weight appeared to be the most important covariate and explained a major part of the observed variability in the pharmacokinetics of busulfan. None of the studied polymorphisms in the genes encoding GSTA1 GSTM1, GSTP1, and GSTT1 nor combinations of genotypes were significant covariates. It was concluded that in children, variability in pharmacokinetics of busulfan could not be related to polymorphisms in GST.
Asunto(s)
Antineoplásicos Alquilantes/farmacocinética , Busulfano/farmacocinética , Glutatión Transferasa/genética , Adolescente , Adulto , Antineoplásicos Alquilantes/administración & dosificación , Busulfano/administración & dosificación , Niño , Preescolar , ADN/biosíntesis , ADN/genética , Femenino , Variación Genética , Genotipo , Enfermedad Veno-Oclusiva Hepática/complicaciones , Enfermedad Veno-Oclusiva Hepática/diagnóstico , Humanos , Lactante , Inyecciones Intravenosas , Masculino , Modelos Estadísticos , Polimorfismo Genético/genética , Población , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
Trough (C0) monitoring is not optimal for therapeutic drug monitoring of tacrolimus. To better estimate systemic exposure of tacrolimus and achieve clinical benefit, an improved therapeutic drug monitoring strategy should be developed. The authors examined which single and combination of time points best estimated the empiric "gold standard" AUC0-12h and developed and validated a new, flexible, and accurate limited sampling model for monitoring tacrolimus in patients having undergone liver transplantation. Twenty-three stable patients with full AUC0-12h were divided into two groups based on area under the concentration-time curve/dose. With multiple regression analysis, limited sampling formulae were derived and population-pharmacokinetic-based limited sampling models were developed and validated. A regression analysis was performed between either area under the concentration-time curves calculated with formulae or models with the reference trapezoidal AUC0-12h. Both formulae and models based on single samples C4-C6 (r2 = 0.94 [MPE/MAPE 0/7]-0.90 [2/8] and 0.97 [0/7]-0.97 [1/5]) showed excellent performance. The calculated area under the concentration-time curve target range for tacrolimus was 90 to 130 h*microg/L. Multiple point sampling performed better, especially when using models (r2 > 0.94). C0 was a less precise predictor of AUC0-12h compared with both formulae and models (r2's 0.68 [5/17] and 0.87 [2/14]). In conclusion, trough concentration monitoring is not an accurate method for assessing systemic exposure to tacrolimus in stable patients having undergone liver transplantation. This new limited sampling model, based on single time points C4-C6, shows excellent performance in estimating the AUC0-12h.
Asunto(s)
Inmunosupresores/farmacocinética , Trasplante de Hígado/inmunología , Tacrolimus/farmacocinética , Adulto , Anciano , Área Bajo la Curva , Femenino , Humanos , Inmunosupresores/sangre , Inmunosupresores/uso terapéutico , Masculino , Persona de Mediana Edad , Modelos Estadísticos , Población , Análisis de Regresión , Muestreo , Tacrolimus/sangre , Tacrolimus/uso terapéutico , Adulto JovenRESUMEN
PURPOSE: This study was designed to determine the effects of P-glycoprotein (P-gp) and cytochrome P450 3a metabolism on the oral bioavailability of the vinca alkaloid Vinorelbine (Navelbine; VRL). METHODS: Pharmacokinetics of VRL were determined in FVB wild-type and mdr1a/1b (-/-) mice after oral and intravenous administration of 10 mg/kg VRL with or without oral ritonavir (5 mg/kg) prior to VRL. Serial blood samples were drawn for a period of up to 48 hours using mice with a cannulated jugular vein. Feces was collected for a period of 96 hours. VRL was determined by ion-exchange HPLC in combination with fluorescence detection. RESULTS: The oral bioavailability in wild-type was 16.0+/-1.4% (mean+/-SE) and was not significantly higher in mdr1a/1b (-/-) mice (17.9+/-0.7%). Both after intravenous and oral administration, the AUC was not significantly different between wild-type and mdr1a/1b(-/-) mice. When RTV was co-administered the AUC of intravenous VRL increased significantly by 30% (p = 0.012). Because RTV increased the AUC of oral VRL by 83% the oral bioavailability was increased to 22.5+/-2.3% (p = 0.016). The fecal recovery of unchanged VRL was about 34 and 6% of the dose in wild-type and mdr1a/1b(-/-) mice, respectively, and was not altered by RTV. CONCLUSION: This study shows that P-gp has little effect on the disposition and oral bioavailability of VRL. A substantial fraction of an oral dose of VRL is absorbed from the gut of wild-type mice. Consequently, first-pass metabolism is the most important factor for explaining the modest oral bioavailability, but the results with RTV suggest that cyp3a plays only a modest role in metabolic breakdown in mice. Apparently, other routes of metabolic elimination are more important. These results suggest that also in patients the oral bioavailability may not gain substantially from the co-administration of a potent P-gp and/or Cyp3a inhibitor.